The potential of BTKi therapies in delaying MS progression
touchEXPERT FOCUS for touchNEUROLOGY
Join Prof. Montalban as he shares expert insights into the pathophysiology of progressive MS and the rationale for targeting BTK inhibitors. He reviews emerging clinical data supporting the use of BTK inhibitors and discusses how they may fit into the evolving treatment landscape. In this context, Prof. Montalban also considers current guideline-recommended therapies for progressive MS and highlights key areas of remaining unmet treatment need.
The expert
Prof. Xavier Montalban, Centre d'Esclerosi Múltiple de Catalunya (Cemcat) and Vall d'Hebron University…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.